. .�the kind of review being proposed does not, at least initially, appear to bring anything new or needed to is already a robust system of oversight,� mogulof said in the statement. http://lm360.us/Dede-sister-of-Stahlman-from-Lang?Squadrito=260 pharma exports can cross bn by 2020: chief of pharmexcil